Home>>Signaling Pathways>> Cancer Biology>>SIKVAV (acetate)

SIKVAV (acetate) (Synonyms: Hexapeptide-10, Ser-Ile-Lys-Val-Ala-Val)

Catalog No.GC49713

A laminin α1-derived peptide

Products are for research use only. Not for human use. We do not sell to patients.

SIKVAV (acetate) Chemical Structure

Cas No.: N/A

Size Price Stock Qty
100 mg
$63.00
In stock
500 mg
$271.00
In stock
1 g
$480.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

SIKVAV is a laminin α1-derived peptide.1 It binds to α3, α6, and β1 integrins and induces adhesion of CAC2 adenoid cystic carcinoma cells when used at a concentration of 1 µg/ml. SIKVAV (100 µg/ml) stimulates the proliferation and migration of primary mouse fibroblasts, as well as induces the secretion of EGF, VEGF, TGF-β, and FGF in the same cells.2 Topical administration of a chitosan hydrogel containing SIKVAV promotes wound healing and angiogenesis in mice.

1.Freitas, V.M., Vilas-Boas, V.F., Pimenta, D.C., et al.SIKVAV, a laminin α1-derived peptide, interacts with integrins and increases protease activity of a human salivary gland adenoid cystic carcinoma cell line through the ERK 1/2 signaling pathwayAm. J. Pathol.171(1)124-138(2007) 2.Chen, X., Zhang, M., Chen, S., et al.Peptide-modified chitosan hydrogels accelerate skin wound healing by promoting fibroblast proliferation, migration, and secretionCell Transplant.26(8)1331-1340(2017)

Reviews

Review for SIKVAV (acetate)

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SIKVAV (acetate)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.